3B Future Health Fund
VC Fund
Monaco, Germany
3B Future Health Fund is a VC fund in Monaco focused on Biotechnology and Therapeutics. Helsinn Investment Fund S.A. is a Luxembourg fund focused on early-stage investments in areas of high unmet patient need.
- Total investments:
- 36
- Last investment:
- Lead investor:
- 33%
- Last fund:
Last updated:
For AI agents: llms.txt
Industries 3B Future Health Fund invests in
Stages 3B Future Health Fund invests in
Countries 3B Future Health Fund invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series A
- $2.7M–$41M
- Series B
- $7.4M–$75M
Investment Focus
Industry
- Biotechnology 19 (53%)
- Therapeutics 8 (22%)
- Medical 7 (19%)
- Biopharma 7 (19%)
- Health Care 7 (19%)
Stage
- Series B 10 (28%)
- Series A 7 (19%)
- Funding Round 3 (8%)
- Seed 2 (6%)
- Series C 2 (6%)
Country
- United States 7 (19%)
- Italy 3 (8%)
- United Kingdom 3 (8%)
- France 2 (6%)
- Switzerland 2 (6%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Carlos von Bonhorst
Strategic Consultant
|
Strategic Consultant | Total investments: 0 | Find email | |
Marianne Bjordal
Partner
|
Partner | Total investments: 4 | Find email | |
Riccardo Braglia
Vice Chairman and Chief Executive Officer
|
Vice Chairman and Chief Executive Officer | Total investments: 8 | Find email | |
Francesco Granata
Consultant
|
Consultant | Total investments: 0 | Find email | |
Karin Hehenberger
Medical and Scientific Consultant
|
Medical and Scientific Consultant | Total investments: 1 | Find email | |
| See all 6 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Kainova Therapeutics
|
Domain Therapeutics is a biopharmaceutical company located in Strasbourg, France, dedicated to the discovery and early development of small molecules targeting G-coupled Protein Receptors (GPCRs), one of the best classes of drug targets. Domain Therapeutics is using its innovative and proprietary technology platform DTect-Allâ„¢ to identifyorthosteric and allosteric ligands of GPCRs, including the so called Silent Allosteric Modulators (SAMs) that represent a unique source of compounds that cannot be discovered by standard technologies. DTect-Allâ„¢ is able to address difficult GPCRs such as orphan and peptidic GPCRs. | $23.5M / Series B / Feb 09, 2026 | |
Fore Biotherapeutics
|
We are a precision oncology company pioneering the development of cancer therapies guided by our proprietary functional genomics. | $40.2M / Series D / May 06, 2025 | |
Epsilogen
|
IGEM Therapeutics is a developer of an immuno-oncology company intended to develop immunoglobulin antibodies to treat cancer.The company's offerings include IgE-based drugs targeting solid tumors, enabling patients to kill parasites which reside in human tissue, also the home of the solid tumor. | $16.3M / Series B / Sep 09, 2024 | |
iOnctura
|
iOnctura is a biopharmaceutical company focusing on novel therapeutics to modulate key culprits of immunosuppression in the tumor microenvironment. Immune checkpoint inhibitors (eg PD/PD-L1) have shown remarkable effectiveness for some but not for all cancer patients. The company aims to improve current immune checkpoint therapies bydeveloping novel drugs with potential safety and efficacy profiles that when combined with checkpoint inhibition have the potential to optimize clinical outcomes. Through its partnerships with Merck and Cancer Research Technology (the commercial arm of Cancer Research UK, London, UK), iOnctura has established a pipeline of preclinical molecules to advance towards the clinic in combination with immuno-oncology assets from Merck. iOnctura is supported by a world renowned scientific advisory board and, with its access to CRT’s drug discovery labs and network of academic collaborators, is well-positioned to rapidly establish novel combination therapies in the field of cancer immunology. | $85.7M / Series B / Jun 20, 2024 | |
NeoPhore
|
NeoPhore is a provider of novel small molecule therapies intended to treat cancer through stimulation of the immune system.The company's small molecule therapies target genetic mechanisms in order to create neoantigen which is known to stimulate the immune system and potentially be a weak spot in a tumor cell's defense mechanisms,enabling cancer patients to get treated and achieve improved clinical outcomes. | $12.2M / Series B / Feb 01, 2024 | |
On Target Laboratories
|
On Target Laboratories, LLC engages in discovering, developing, and commercializing small molecules that target specific pathological cells, when conjugated with fluorescent dyes. It offers folate and other targeting agents that target, lung, uterine, kidney, breast, colon, pancreatic, and prostate cancer cells. The company was incorporated in 2010and is based in Northbrook, Illinois. | $30M / Series C / Nov 16, 2023 | |
|
Fore Biotherapeutics
|
We are a precision oncology company pioneering the development of cancer therapies guided by our proprietary functional genomics. | $75M / Series D / Aug 23, 2023 | |
OncoResponse
|
OncoResponse Inc., an immuno-oncology company located in Houston, Texas, has partnered with MD Anderson Cancer Center (MDACC) to deploy a unique and transformational approach to cancer therapeutic monoclonal antibody and target discovery. The company licensed the I-STAR™ platform, developed and validated by Theraclone Sciences of Seattle, tointerrogate the human memory B-cell repertoire of cancer patients who are considered “Elite Responders” to immunotherapy; as such, their own adaptive immune system responded to immunotherapy stimulation in a way that achieved curative or durable responses. From these Elite Responders, OncoResponse is leveraging the human immune system to identify fully human monoclonal antibodies and discover novel targets that will lead to the development of fully human antibody derived therapeutics for the treatment of cancer. | $14M / Series D / May 18, 2023 | |
Geneos Therapeutics
|
Geneos is developer of a neo-antigen based personalized immunotherapy designed to offer cancer treatment. The company's technology is designed to identify relevant neoantigen targets from individual patient tumors to develop novel treatments for cancer, providing patients with tumor targeted immunotherapies to cure their disease. | $5M / Series A / Apr 12, 2023 | |
|
Geneos Therapeutics
|
Geneos is developer of a neo-antigen based personalized immunotherapy designed to offer cancer treatment. The company's technology is designed to identify relevant neoantigen targets from individual patient tumors to develop novel treatments for cancer, providing patients with tumor targeted immunotherapies to cure their disease. | $5M / Series A / Apr 12, 2023 | |
| See all 36 investments → | |||
Co-Investors
Claris Ventures
5 deals together
Novartis Venture Fund
5 deals together
VI Partners
5 deals together
Schroders Capital
4 deals together
Astellas Venture Management
3 deals together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does 3B Future Health Fund invest in?
3B Future Health Fund invests primarily in Biotechnology, Therapeutics and Medical startups, most often at Series B and Series A stage. Most of the 36 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is 3B Future Health Fund's check size?
3B Future Health Fund typically joins rounds of $2.7M–$41M at Series A and $7.4M–$75M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds 3B Future Health Fund participates in.
How do I contact 3B Future Health Fund?
Public channels for 3B Future Health Fund include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at 3B Future Health Fund?
The team at 3B Future Health Fund includes Carlos von Bonhorst (Strategic Consultant), Marianne Bjordal (Partner) and Riccardo Braglia (Vice Chairman and Chief Executive Officer), among 6 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
